Inclusion Criteria:

- Organ transplant recipients with stable transplant function and who received their
transplant at least 2 years prior to study entry

- Organ transplant patients who have had at least one biopsy-positive SCC

- Aged 18 - 75 years

- Written informed consent to the performance of all study-specific procedures

Exclusion Criteria:

- Allergy to afamelanotide (CUV1647) or the polymer contained in the implant

- History of melanoma

- Current pigmentary disorders such as melasma

- Diagnosed with HIV/AIDS, or hepatitis B or C

- Current history of drug or alcohol abuse (in the last 12 months)

- Clinically significant organ dysfunction, history of medical disorders or other
factors, which in the opinion of the investigator will interfere with the
interpretation of study outcome measures

- Major medical or psychiatric illness

- Pregnancy as confirmed by positive serum beta-HCG pregnancy test prior to baseline or
lactating mothers

- Females of child bearing potential not using adequate contraceptive measures

- Participation in a clinical trial for an investigational agent within 30 days prior
to the screening visit

- Use of regular medications or any other factors that may affect skin pigmentation

Discontinuation Criteria:

- Initiation of treatment with systemic retinoids

- Change of class of systemic immunosuppressant treatment